Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2022

01-02-2022 | Positron Emission Tomography | Commentary

Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology

Authors: Federica Pisaneschi, Nerissa T. Viola

Published in: Molecular Imaging and Biology | Issue 1/2022

Login to get access

Abstract

In oncology, biomarker research aimed to provide insights on cancer biology via positron emission tomography (PET) and single photon emission tomography (SPECT) imaging has seen an incredible growth in the past two decades. Despite the increased number of publications on PET/SPECT radiopharmaceuticals, the field lacked standardization of in vitro and in vivo parameters necessary for the characterization of any radiotracer. Through the efforts of the World Molecular Imaging Society Education Committee, this white paper lays down validation studies that are essential to chemically and biologically characterize new radiopharmaceuticals derived from small molecules, peptides or proteins. Finally, a brief overview of the steps toward translation is also presented.
Herein, we discuss the following:
  • Chemistry and radiochemistry metrics to establish the identity of the imaging agent.
  • In vitro and in vivo studies to examine the radiotracer’s mechanism of action, which includes target specificity, pharmacokinetics and in vivo metabolism.
Literature
1.
Stephens K (2020) FDA OKs First PSMA-targeted PET imaging drug for men with prostate cancer. AXIS Imaging News
2.
Lantheus Receives U.S. FDA approval of PYLARIFY® (piflufolastat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. Published online May 27, 2021. https://​bwnews.​pr/​3vtMgBh.​ Accessed May 27, 2021
3.
Lewis J, Windhorst AD, Zeglis BM (2019) Radiopharmaceutical chemistry
4.
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD (2017) Consensus nomenclature rules for radiopharmaceutical chemistry — setting the record straight. Nucl Med Biol 55:v–xiCrossRef
5.
Herth MM, Ametamey S, Antuganov D, Bauman A, Berndt M, Brooks AF, Bormans G, Choe YS, Gillings N, Häfeli UO, James ML, Kopka K, Kramer V, Krasikova R, Madsen J, Mu L, Neumaier B, Piel M, Rösch F, Ross T, Schibli R, Scott PJH, Shalgunov V, Vasdev N, Wadsak W, Zeglis BM (2021) On the consensus nomenclature rules for radiopharmaceutical chemistry – reconsideration of radiochemical conversion. Nucl Med Biol 93:19–21CrossRef
6.
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD (2019) Status of the ‘consensus nomenclature rules in radiopharmaceutical sciences’ initiative. Nucl Med Biol 71:19–22CrossRef
7.
Yang DJ, Azhdarinia A, Kim EE (2004) Automated Synthesis of Radiopharmaceuticals. In: Kim EE, Lee MC, Inoue T, Wong WH (eds) Clinical PET. Springer, New York
8.
Spreckelmeyer S, Balzer M, Poetzsch S, Brenner W (2020) Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application. EJNMMI Radiopharm Chem 5(1):31CrossRef
9.
Aalbersberg EA, van Andel L, Geluk-Jonker MM, Beijnen JH, Stokkel MPM, Hendrikx JJMA (2020) Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow). EJNMMI Radiopharm Chem 5(1):10–10CrossRef
10.
Caroli P, Colangione SP, De Giorgi U, Ghigi G, Celli M, Scarpi E, Monti M, Di Iorio V, Sarnelli A, Paganelli G, Matteucci F, Romeo A (2020) 68Ga-PSMA-11 PET/CT-guided stereotactic body radiation therapy retreatment in prostate cancer patients with PSA failure after salvage radiotherapy. Biomedicines 8(12):536CrossRef
11.
de Vries LH, Lodewijk L, Braat AJAT, Krijger GC, Valk GD, Lam MGEH, Borel Rinkes IHM, Vriens MR, de Keizer B (2020) 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617. EJNMMI Res 10(1):18CrossRef
12.
Calderoni L, Farolfi A, Pianori D, Maietti E, Cabitza V, Lambertini A, Ricci G, Telo S, Lodi F, Castellucci P, Fanti S (2019) Automated synthesis module and sterile cold kit for 68Ga-PSMA-11 do not show differences in PET/CT image quality. J Nucl Med jnumed.119.231605
13.
Choe YS, Lidström PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA (1995) Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem 38(5):816–825CrossRef
14.
Collier TL, Dahl K, Stephenson NA, Holland JP, Riley A, Liang SH, Vasdev N (2018) Recent applications of a single quadrupole mass spectrometer in 11C, 18F and radiometal chemistry. J Fluorine Chem 210:46–55CrossRef
15.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(8):493–507CrossRef
16.
Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, Anderson CJ, Edwards WB, Ferris RL (2017) Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology 6(7):e1329071–e1329071CrossRef
17.
Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ (2018) A preclinical assessment of (89)Zr-atezolizumab identifies a requirement for carrier added formulations not observed with (89)Zr-C4. Bioconjug Chem 29(10):3476–3482CrossRef
18.
Anderson CJ, Schwarz SW, Connett JM, Cutler PD, Guo LW, Germain CJ, Philpott GW, Zinn KR, Greiner DP, Meares CF et al (1995) Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab’)2. J Nucl Med 36(5):850–858PubMed
19.
Zeglis BM, Lewis JS (2015) The bioconjugation and radiosynthesis of 89Zr-DFO-labeled Antibodies. JoVE 96:e52521
20.
National Center for Biotechnology Information (2021) PubChem Patent Summary for DK-2419096-T3. Retrieved July 22, 2021 from https://​pubchem.​ncbi.​nlm.​nih.​gov/​patent/​DK-2419096-T3
21.
Dux R, Kindler-Röhrborn A, Lennartz K, Rajewsky MF (1991) Determination of immunoreactive fraction and kinetic parameters of a radiolabeled monoclonal antibody in the absence of antigen excess. J Immunol Methods 144(2):175–183CrossRef
22.
Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, Bander N, Goldsmith S (2004) Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother Radiopharm 19(6):706–715CrossRef
23.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr., (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72(1):77–89CrossRef
24.
Mattes MJ (1995) Limitations of the Lindmo method in determining antibody immunoreactivity. Int J Cancer 61(2):286–288CrossRef
25.
Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS (2019) A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl Med Biol 71:32–38CrossRef
26.
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61(12):4750–4755PubMed
27.
Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48(24 Pt 1):7022–7032PubMed
28.
Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63(6):1288–1296PubMed
29.
Zhang Y, Fox GB (2012) PET imaging for receptor occupancy: meditations on calculation and simplification. J Biomed Res 26(2):69–76CrossRef
30.
Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, Anderson CJ (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47(6):1465–1474CrossRef
31.
Pisaneschi F, Nguyen QD, Shamsaei E, Glaser M, Robins E, Kaliszczak M, Smith G, Spivey AC, Aboagye EO (2010) Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation. Bioorg Med Chem 18(18):6634–6645CrossRef
32.
Kręcisz P, Czarnecka K, Królicki L, Mikiciuk-Olasik E, Szymański P (2021) Radiolabeled peptides and antibodies in medicine. Bioconjug Chem 32(1):25–42CrossRef
33.
Izuishi K, Yamamoto Y, Mori H, Kameyama R, Fujihara S, Masaki T, Suzuki Y (2014) Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer. Oncol Rep 31(2):701–706CrossRef
34.
Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D (2019) Mechanism-specific pharmacodynamics of a novel Complex-I inhibitor quantified by imaging reversal of consumptive hypoxia with [(18)F]FAZA PET in vivo. Cells 8(12):1487CrossRef
35.
Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC, Millward SW (2018) Caspase-3 substrates for noninvasive pharmacodynamic imaging of apoptosis by PET/CT. Bioconjug Chem 29(9):3180–3195CrossRef
36.
Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS (2018) Fc-Mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res 78(7):1820–1832CrossRef
37.
Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to assess ASCT2 expression in lung cancer. Mol Imaging Biol 18(1):18–23CrossRef
38.
Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB (2015) Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 7(274):274ra17CrossRef
39.
Zhou R, Pantel AR, Li S, Lieberman BP, Ploessl K, Choi H, Blankemeyer E, Lee H, Kung HF, Mach RH, Mankoff DA (2017) [(18)F](2S,4R)4-Fluoroglutamine PET detects glutamine pool size changes in triple-negative breast cancer in response to glutaminase inhibition. Can Res 77(6):1476–1484CrossRef
40.
Zhou D, Chu W, Xu J, Jones LA, Peng X, Li S, Chen DL, Mach RH (2014) Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem 22(5):1700–1707CrossRef
41.
Sharma R, Aboagye E (2011) Development of radiotracers for oncology—the interface with pharmacology. Br J Pharmacol 163(8):1565–1585CrossRef
42.
Schindler E, Amantea MA, Karlsson MO, Friberg LE (2016) PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor. CPT Pharmacometr Syst Pharmacol 5(4):173–181CrossRef
43.
Challapalli A, Aboagye EO (2016) Positron Emission tomography imaging of tumor cell metabolism and application to therapy response monitoring. Front Oncol 6:44CrossRef
44.
Workman P, Aboagye EO, Chung Y-L, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit J, Committee, F. t. C. R. U. P. P. T. A. (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98(9):580–598CrossRef
45.
Zhang Z, Gogarty KR, Daryaee F, Tonge PJ (2017) Pharmacokinetic and pharmacodynamics relationships. In: Jain SK (ed) Imaging Infections: From Bench to Bedside. Springer International Publishing, Cham, pp 195–207CrossRef
46.
Schwarz SW, Dick D, VanBrocklin HF, Hoffman JM (2014) Regulatory requirements for PET drug production. J Nucl Med jnumed.113.132472
Metadata
Title
Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology
Authors
Federica Pisaneschi
Nerissa T. Viola
Publication date
01-02-2022
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 1/2022
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-021-01645-6

Other articles of this Issue 1/2022

Molecular Imaging and Biology 1/2022 Go to the issue

Research Article

PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features

Research Article

Direct Comparison of [18F]F-DPA with [18F]DPA-714 and [11C]PBR28 for Neuroinflammation Imaging in the same Alzheimer’s Disease Model Mice and Healthy Controls

Research Article

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET

Research Article

Molecular Imaging Reveals a High Degree of Cross-Seeding of Spontaneous Metastases in a Novel Mouse Model of Synchronous Bilateral Breast Cancer

Brief Article

Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging

Publisher Correction

Publisher Correction to: PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features